Table 1.
Summary % (n) of dose-finding oncology trials that implemented a model-based or novel design by agent type and year of publication
| Year | MTA | Immuno Therapy |
Chemo Therapy |
Radiation Therapy |
Other Therapy† |
All Therapies |
|---|---|---|---|---|---|---|
| 2008 | 3.4% (3/87)* |
0% (0/13) |
5.5% (6/109) |
14.3% (1/7) |
9.1% (1/11) |
4.8% (11/227) |
| 2009 | 3.1% (2/65) |
22.2% (2/9) |
0% (0/116) |
9.1% (1/11) |
0% (0/11) |
2.4% (5/212) |
| 2010 | 3.5% (4/115) |
0% (0/16) |
2.1% (2/95) |
0% (0/9) |
0% (0/14) |
2.4% (6/249) |
| 2011 | 7.5% (8/107) |
8.3% (1/12) |
4.2% (4/95) |
0% (0/8) |
8.7% (2/23) |
6.1% (15/245) |
| 2012 | 6.5% (11/170) |
9.1% (1/11) |
1.8% (3/81) |
18.2% (2/11) |
17.6% (3/17) |
6.9% (20/290) |
| 2013 | 4.8% (8/166) |
5.6% (1/18) |
1.8% (1/55) |
11.1% (1/9) |
13.3% (2/15) |
4.9% (13/263) |
| 2014 | 9.8% (14/143) |
0% (0/6) |
13.8% (8/58) |
0% (0/5) |
0% (0/14) |
9.7% (22/226) |
*
In parentheses for a given year, the numerator represents the number of trials that used a model-based or novel design; the denominator represents the total number of trials that investigated a particular agent
†
One article with unspecified agent was included in the ‘Other Therapy’ category